{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:56:10Z","timestamp":1790337370171,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["Mildred-Scheel scholarship No.70114570"],"award-info":[{"award-number":["Mildred-Scheel scholarship No.70114570"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Honoraria from GSK and Novartis"},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL131835, R01 HL167139"],"award-info":[{"award-number":["R01HL131835, R01 HL167139"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2110909"],"award-info":[{"award-number":["W81XWH2110909"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009784","name":"Starr Foundation","doi-asserted-by":"publisher","award":["I15-0026"],"award-info":[{"award-number":["I15-0026"]}],"id":[{"id":"10.13039\/100009784","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41375-026-02885-7","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:27:13Z","timestamp":1771936033000},"page":"773-782","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Risk stratification of patients with TP53-mutated myeloproliferative neoplasms"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7393-861X","authenticated-orcid":false,"given":"Benjamin","family":"Rolles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3317-0837","authenticated-orcid":false,"given":"Cilomar Martins de Oliveira","family":"Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Fergusson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-0902","authenticated-orcid":false,"given":"Jan Philipp","family":"Bewersdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecelia","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0778-9230","authenticated-orcid":false,"given":"Matthew","family":"Schwede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9692-1634","authenticated-orcid":false,"given":"James","family":"England","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-4529","authenticated-orcid":false,"given":"Marlise R.","family":"Luskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7865-2306","authenticated-orcid":false,"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7245-9652","authenticated-orcid":false,"given":"Shai","family":"Shimony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mifra","family":"Faiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Addison C.","family":"Hillerbrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chulwoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8726-6212","authenticated-orcid":false,"given":"Lachelle D.","family":"Weeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Waldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Wazir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6421-0117","authenticated-orcid":false,"given":"Joan","family":"How","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9065-0581","authenticated-orcid":false,"given":"Anna E.","family":"Marneth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Aryee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raajit","family":"Rampal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison K.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8253-6156","authenticated-orcid":false,"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1419-8607","authenticated-orcid":false,"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9727-8495","authenticated-orcid":false,"given":"Ann","family":"Mullally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"2885_CR1","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","volume":"36","author":"P Guglielmelli","year":"2018","unstructured":"Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018;36:310\u20138.","journal-title":"J Clin Oncol."},{"key":"2885_CR2","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018;32:1631\u201342.","journal-title":"Leukemia"},{"key":"2885_CR3","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/bjh.16380","volume":"189","author":"A Tefferi","year":"2020","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020;189:291\u2013302.","journal-title":"Br J Haematol"},{"key":"2885_CR4","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"2885_CR5","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1182\/bloodadvances.2018021469","volume":"2","author":"CJ McNamara","year":"2018","unstructured":"McNamara CJ, Panzarella T, Kennedy JA, Arruda A, Claudio JO, Daher-Reyes G, et al. The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes. Blood Adv. 2018;2:2658\u201371.","journal-title":"Blood Adv"},{"key":"2885_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/ajh.27136","volume":"99","author":"GG Loscocco","year":"2024","unstructured":"Loscocco GG, Rotunno G, Mannelli F, Coltro G, Gesullo F, Pancani F, et al. The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70\/plus\/plus v2.0) for primary myelofibrosis. Am J Hematol. 2024;99:68\u201378.","journal-title":"Am J Hematol"},{"key":"2885_CR7","first-page":"2901","volume":"141","author":"N Gagelmann","year":"2023","unstructured":"Gagelmann N, Badbaran A, Salit RB, Schroeder T, Gurnari C, Pagliuca S, et al. Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation. Blood. 2023;141:2901\u201311.","journal-title":"Blood"},{"key":"2885_CR8","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/ajh.22216","volume":"87","author":"S Raza","year":"2012","unstructured":"Raza S, Viswanatha D, Frederick L, Lasho T, Finke C, Knudson R, et al. TP53 mutations and polymorphisms in primary myelofibrosis. Am J Hematol. 2012;87:204\u20136.","journal-title":"Am J Hematol"},{"key":"2885_CR9","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/leu.2017.230","volume":"32","author":"B Kubesova","year":"2018","unstructured":"Kubesova B, Pavlova S, Malcikova J, Kabathova J, Radova L, Tom N, et al. Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. Leukemia. 2018;32:450\u201361.","journal-title":"Leukemia"},{"key":"2885_CR10","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379:1416\u201330.","journal-title":"N Engl J Med"},{"key":"2885_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13542-2","volume":"10","author":"S Chen","year":"2019","unstructured":"Chen S, Wang Q, Yu H, Capitano ML, Vemula S, Nabinger SC, et al. Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway. Nat Commun. 2019;10:5649.","journal-title":"Nat Commun"},{"key":"2885_CR12","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41588-018-0204-y","volume":"50","author":"AO Giacomelli","year":"2018","unstructured":"Giacomelli AO, Yang X, Lintner RE, McFarland JM, Duby M, Kim J, et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018;50:1381\u20137.","journal-title":"Nat Genet"},{"key":"2885_CR13","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41588-024-02039-4","volume":"57","author":"JS Funk","year":"2025","unstructured":"Funk JS, Klimovich M, Drangenstein D, Pielhoop O, Hunold P, Borowek A, et al. Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations. Nat Genet. 2025;57:140\u201353.","journal-title":"Nat Genet"},{"key":"2885_CR14","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1126\/science.aax3649","volume":"365","author":"S Boettcher","year":"2019","unstructured":"Boettcher S, Miller PG, Sharma R, McConkey M, Leventhal M, Krivtsov AV, et al. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science. 2019;365:599\u2013604.","journal-title":"Science"},{"key":"2885_CR15","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/ajh.27609","volume":"100","author":"A Tefferi","year":"2025","unstructured":"Tefferi A, Abdelmagid M, Loscocco GG, Fathima S, Begna KH, Al-Kali A, et al. TP53 mutations in myeloproliferative neoplasms: context-dependent evaluation of prognostic relevance. Am J Hematol. 2025;100:552\u201360.","journal-title":"Am J Hematol"},{"key":"2885_CR16","doi-asserted-by":"crossref","unstructured":"Badar T, Foran JM, Bewersdorf JP, Wang Y-H, Coltoff A, El Kettani M, et al. Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational status. Br JHaematol 2025;207:683\u20136.","DOI":"10.1111\/bjh.20187"},{"key":"2885_CR17","doi-asserted-by":"crossref","unstructured":"Senapati J, Loghavi S, Garcia-Manero G, Tang G, Kadia T, Short NJ, et al. Clinical interrogation of TP53 aberrations and their impact on survival in patients with myeloid neoplasms. Haematologica 2024;110:1304\u201315.","DOI":"10.3324\/haematol.2025.289205"},{"key":"2885_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-023-01480-y","volume":"16","author":"W Bahaj","year":"2023","unstructured":"Bahaj W, Kewan T, Gurnari C, Durmaz A, Ponvilawan B, Pandit I, et al. Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia. J Hematol Oncol. 2023;16:91.","journal-title":"J Hematol Oncol"},{"key":"2885_CR19","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2885_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01290-0","volume":"15","author":"MV Shah","year":"2025","unstructured":"Shah MV, Hung K, Baranwal A, Wechalekar G, Al-Kali A, Toop CR, et al. Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort. Blood Cancer J. 2025;15:88.","journal-title":"Blood Cancer J"},{"key":"2885_CR21","doi-asserted-by":"crossref","unstructured":"Yabe M, Omarbekova AZ, Hsu M, May H, Arcila ME, Liu Y, et al. TP53 combined phenotype score is associated with the clinical outcome of TP53-mutated myelodysplastic syndromes. Cancers 2021;13:5502.","DOI":"10.3390\/cancers13215502"},{"key":"2885_CR22","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1038\/leu.2013.119","volume":"27","author":"AM Vannucchi","year":"2013","unstructured":"Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27:1861\u20139.","journal-title":"Leukemia"},{"key":"2885_CR23","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","volume":"36","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, et al. MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018;36:1769\u201370.","journal-title":"J Clin Oncol"},{"key":"2885_CR24","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","volume":"26","author":"E Bernard","year":"2020","unstructured":"Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26:1549\u201356.","journal-title":"Nat Med"},{"key":"2885_CR25","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1182\/bloodadvances.2021005867","volume":"6","author":"N Maslah","year":"2022","unstructured":"Maslah N, Verger E, Giraudier S, Chea M, Hoffman R, Mascarenhas J, et al. Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition. Blood Adv. 2022;6:2813\u201323.","journal-title":"Blood Adv"},{"key":"2885_CR26","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1158\/2159-8290.CD-23-1416","volume":"14","author":"S Demajo","year":"2024","unstructured":"Demajo S, Ramis-Zaldivar JE, Mui\u00f1os F, Grau ML, Andrianova M, L\u00f3pez-Bigas N, et al. Identification of clonal hematopoiesis driver mutations through in silico saturation mutagenesis. Cancer Discov. 2024;14:1717\u201331.","journal-title":"Cancer Discov"},{"key":"2885_CR27","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.3390\/cancers14122984","volume":"14","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Guo J, Zhao S, Wang R, Shi L, Fang Y, et al. Bone marrow fibrosis at diagnosis and during the course of disease is associated with TP53 mutations and adverse prognosis in primary myelodysplastic syndrome. Cancers. 2022;14:2984.","journal-title":"Cancers"},{"key":"2885_CR28","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3390\/cancers16030514","volume":"16","author":"T Verma","year":"2024","unstructured":"Verma T, Papadantonakis N, Peker Barclift D, Zhang L. Molecular genetic profile of myelofibrosis: implications in the diagnosis, prognosis, and treatment advancements. Cancers. 2024;16:514.","journal-title":"Cancers"},{"key":"2885_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06702-w","volume":"15","author":"Y-N Bao","year":"2024","unstructured":"Bao Y-N, Yang Q, Shen X-L, Yu W-K, Zhou L, Zhu Q-R, et al. Targeting tumor suppressor p53 for organ fibrosis therapy. Cell Death Dis. 2024;15:336.","journal-title":"Cell Death Dis"},{"key":"2885_CR30","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/s41588-023-01480-1","volume":"55","author":"A Rodriguez-Meira","year":"2023","unstructured":"Rodriguez-Meira A, Norfo R, Wen S, Ch\u00e9deville AL, Rahman H, O\u2019Sullivan J, et al. Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution. Nat Genet. 2023;55:1531\u201341.","journal-title":"Nat Genet"},{"key":"2885_CR31","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.clml.2020.01.003","volume":"20","author":"M Melody","year":"2020","unstructured":"Melody M, Al Ali N, Zhang L, Ramadan H, Padron E, Sallman D, et al. Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2020;20:324\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2885_CR32","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/bjh.14656","volume":"181","author":"Duarte","year":"2018","unstructured":"Duarte, Barbosa FB, Jesus Dos Santos MC, Lemes TE, Vasconcelos RPG, Vasconcelos JP, de PRL, et al. Bone marrow fibrosis at diagnosis is associated with TP53 overexpression and adverse prognosis in low-risk myelodysplastic syndrome. Br J Haematol. 2018;181:547\u20139.","journal-title":"Br J Haematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02885-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02885-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02885-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T10:37:25Z","timestamp":1775558245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02885-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2885"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02885-7","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MJA has financial interests in SeQure Dx. MS served on the advisory board for Novartis, Kymera, Sierra Oncology, GSK, Rigel, BMS, Sobi and Syndax, Kura; consulted for Boston Consulting, GLG and Dedham group and participated in CME activity for Novartis, Curis Oncology, Haymarket Media and Clinical Care Options and is a member of the Medical Safety Monitoring Board for Keros Pharmaceuticals. AM has received research funding from Morphic and Incyte and has consulted for Cellarity.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Approval by the Institutional Review Board (IRB) at each participating center was obtained according to their local policies. All participating centers signed a data transfer and use agreement with DFCI.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}